

ASARINA PHARMA AB (PUBL)

YEAR-END REPORT 2021

1 October – 31 December 2021



**REMAIN IN
CONTROL
OF YOUR LIFE**

ASARINA PHARMA AB

(PUBL) 556698-0750

YEAR-END REPORT 2021



ABOUT ASARINA PHARMA

We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA_A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive-compulsive disorder that still lack safe, efficacious pharmaceutical treatments.

ASARINA PHARMA AB

Karolinska Institutet Science Park | Fogdevreten 2, SE 171 65 Solna, Sweden
Peter Nordkild, CEO | Phone +45 25 47 16 46



OVERVIEW

R&D HIGHLIGHTS

TOURETTE SYNDROME

- The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the outstanding data processing agreement and clinical trial agreements for our two clinical study sites in Copenhagen.
- On 16 February 2022 'First Patient First Visit' took place in our phase IIa clinical study in Tourette syndrome, with our first patient randomized on 17 February.

FINANCIAL HIGHLIGHTS

- Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20)
- Cash balance at 31 December 2021 amounted to 21.7 MSEK which will fund the Tourette Study



Jakob Dynnes Hansen
Chief Financial Officer



CEO STATEMENT

DEAR ASARINA SHAREHOLDER,

We enter the new Quarter and Financial Year with renewed energy and optimism. The news in December that Region Hovedstaden had finally cleared its administrative backlog and signed the required papers for our two clinical test sites in Copenhagen was hugely important.

The announcement that followed in February, of 'First Patient First Visit' for our Phase IIa Tourette study, was a breath of fresh air for all of us – allowing us to appreciate afresh the exciting opportunities ahead, as we seek to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.

TOURETTE SYNDROME

Significant events during Q4: On 22 December 2021 the Capital Region of Denmark (Region Hovedstaden) cleared its administrative backlog and was finally able to sign the outstanding data processing agreements and clinical trial agreements for our two clinical Tourette sites in Copenhagen.

Significant events after the reporting period: On 16 February 2022 'First Patient First Visit' took place in our phase IIa clinical study in Tourette syndrome, with our first patient randomized for treatment on 17 February. 30 patients in total will take part, at our two major University Hospital sites in Copenhagen. We expect to publish topline results in Q1 2023.

OBSESSIVE COMPULSIVE DISORDER

Tourette is highly co-morbid – 86% of patients have at least one additional disorder, with OCD being particularly prevalent. Following the US patent granted to Sepranolone for the treatment of OCD in 2021, we remain strongly committed to its potential a new combination therapy (together with SSRIs) for OCD, and continue to explore possibilities for funding of a clinical study.

” *The recent announcement of 'First Patient First Visit' in our phase IIa Tourette Syndrome study was a positive boost. We enter the new Quarter and Financial Year with renewed energy and optimism.*

Peter Nordkild,
CEO Asarina Pharma



THE QUARTER IN-DEPTH

TOURETTE SYNDROME

The phase IIa Proof of Concept study will include 30 patients with or without OCD from the age of 12 to 45 years. 20 patients will receive 10 mg Sepranolone twice weekly for 12 weeks in addition to their standard Tourette treatment, and 10 patients will continue on their standard Tourette treatment.

The study will be conducted at the Danish National Center for Tourette at Herlev and Bispebjerg University hospitals. Bispebjerg will primarily treat the adult patients with Tourette; whilst Herlev University Hospital, a leading research hospital with Scandinavia's largest Tourette department, will focus on children and teenagers.

The expertise and experience both sites have with Tourette patients are of enormous benefit to our study team and will contribute significantly to ensuring smooth patient selection, enrolment and engagement. We expect the first patient to receive the first injection in late February 2022 and to be able to publish topline results in Q1 2023.

OBSESSIVE COMPULSIVE DISORDER

1.5% of women and 1% of men suffer from OCD, yet there is still no safe nor efficacious pharma medication available. The overall efficacy of SSRIs remains <50%. For Asarina Pharma OCD remains a key middle-to long-term priority. This Quarter we have continued our internal assessment of the business case and funding for a study. Our US patent for Sepranolone for OCD, granted in June, was highly encouraging, as was the additional OCD data¹ released in March 2021. These data confirmed that there was a clear connection between increased allopregnanolone levels and worsening of compulsions, as demonstrated in an original human study carried out by Marco Bortolato's team at the University of Utah².

Today OCD is treated with high doses of SSRI's but compliance is low, as less than 50% of patients feel any improvement of their symptoms and even for the patients that have some symptom relief many of these patients stop treatment as they cannot live with common side effects such as weight gain and loss of libido. Whilst SSRIs have some effect on reducing the obsessions inherent in the condition, such as e.g. an abnormal fear of infecting others and desire for cleanliness, the SSRIs have no effect on the associated compulsions e.g. an uncontrollable urge to wash hands incessantly.

Asarina Pharma's OCD treatment concept is based on a combination therapy of SSRIs with Sepranolone, where SSRIs should reduce obsessive anxiety and depression and Sepranolone reduce associated compulsive urges.

” 1.5% of women and 1% of men suffer from OCD worldwide. Our OCD treatment concept is based on a combination therapy of SSRIs with Sepranolone – where SSRIs should reduce obsessive anxiety and depression, and Sepranolone reduce associated compulsive urges

CEO Peter Nordkild

1. Preliminary study of finasteride in Tourette syndrome, Moroni, Bortolato et al, 2011
2. Behavioral fragmentation in the D1CT-7 mouse model of Tourette's syndrome, Bortolato et al 2018



FINANCES

As earlier reported, we have put many activities on hold and the work time of all staff has been further reduced. With these changes we have managed to reduce our cash burn significantly and the present cash will, despite the significant delay of the start of the Tourette study, still cover the cost of the Tourette study, and last till summer 2023.

MOVING FORWARD

As we harness the renewed optimism and energy of our new approval let's remind ourselves of the historic opportunity we face: currently 29% of children with Tourette have tried five or more different medications – with 44% of parents feeling their child's symptoms are not adequately treated by existing therapies (*Tourette Association of America, 2018*). Both ourselves and our esteemed colleagues at the Danish National Center for Tourette look forward keenly to beginning this vital work on a new therapy that, finally, could be effective and safe for the children and adults taking it.

As ever I would like to thank all our shareholders and stakeholders for their patience and continued support as we move forward into the next exciting phase of our journey.

WARM WISHES,



Peter Nordkild,
CEO Asarina Pharma

FINANCIAL OVERVIEW AND OTHER INFORMATION

KEY FINANCIALS

	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC
Net income, KSEK	0	0	0	0
Operating profit/loss, KSEK	-8,702	-24,912	-39,553	-81,406
Profit/loss for the period, KSEK	-8,976	-26,385	-39,566	-82,994
Earnings per share, fully-diluted, SEK	-0.12	-0.95	-1.64	-3.84
Total assets (end of period), KSEK	31,447	68,285	31,447	68,285
Cash and cash equivalents (end-of-period), KSEK	21,715	58,501	21,715	58,501
Equity ratio, %	63.2	77.0	63.2	77.0
Return on equity, %	-11.1	-30.1	-90.9	-87.5
Return on total assets, %	-27.1	-34.6	-78.3	-78.2

REVENUE

Net income in Q4/2021 amounted to 0.0 (0.0) MSEK.

OPERATING EXPENSES

Total operating expenses for the 4th quarter 2021 declined to 8.7 (24.9) MSEK and to 39.6 (81.4) MSEK for the full year. This reflects the modest activity in the second half of 2021 primarily due to the delayed start of the Tourette Study and the various cost reductions which Asarina has implemented during the last 12 – 18 months. Research and development costs dropped to only 7.2 (19.9) MSEK in the 4th quarter and to 29.9 (63.7) MSEK for the full year. Staff costs declined to 0.6 (2.3) MSEK in the quarter and to 5.4 (10.1) MSEK for the year reflecting the reduction in working time for all team members. General and administration costs amounted to 0.8 (2.6) MSEK in 4th quarter and to 3.8 (7.4) MSEK for the whole of 2021.

FINANCIAL ITEMS AND TAX

Financial items (interest expenses as well as currency gains and losses) resulted in the 4th quarter in a loss of 0.3 (1.5) MSEK.

In the 4th quarter, the company booked an estimated income of 6.6 (7.7) MSEK from the Danish tax credit scheme for R&D costs. The tax credit will be paid out in the 4th quarter 2022.

RESULT AND FINANCIAL POSITION

The net result after tax for the 4th quarter 2021 amounted to -2.3 (- 18.6) MSEK and to - 32.9 (-75.3) MSEK for the entire year.

The operating cash flow declined to - 1.4 (-6.8) MSEK in the 4th quarter and to -42.5 (-79.1) MSEK for the full year which confirms the low activity in the second half of 2021. On 31 December 2021, the cash balance at group level amounted to 21.7 (58.5) MSEK which the Company still considers sufficient to finance the phase IIa study in Tourette Syndrome. The shareholders' equity on 31 December 2021 amounted to 19.9 (52.6) MSEK equal to an equity ratio of 63.2 (77.0) %.

STAFF

As of 31 December 2021, Asarina's operating team comprised 8 members (employees and consultants), corresponding to 2½ (3½) full-time employees. The team maintains all core competencies required for the company's R&D activities.

NOTE | Amounts in brackets refer to the corresponding periods or dates in 2020.

THE ASARINA PHARMA SHARE

As of 31 December 2021, Asarina has issued a total of 18,744,524 shares, which are held by an estimated 3,500 shareholders. During the 4th quarter 2021, the major shareholdings changed only moderately.

OWNERSHIP AS OF 31 DECEMBER 2021*

SHAREHOLDER	COUNTRY	NO. OF SHARES	OWNERSHIP (%)
Kurma Biofund	France	3,145,132	16.8
Östersjöstiftelsen (Baltic Foundation)	Sweden	2,667,092	14.2
Idinvest Patrimoine	France	1,639,824	8.7
Fjärde AP-fonden (AP4)	Sweden	1,585,000	8.5
Handelsbanken Läkemedelsfond	Sweden	855,952	4.6
Avanza Pension	Sweden	479,077	2.6
Larsson Utvecklings AB	Sweden	350,000	1.9
Arne Andersson	Sweden	333,689	1.8
Torbjörn Bäckström	Sweden	324,989	1.7
Peter Nordkild (CEO)	Denmark	263,124	1.4
Others		7,100,645	37.9
TOTAL		18,744,524	100.0

* Sources: Euroclear, company estimates

Since 2018, the Company has established three warrant programs for board and staff members comprising 1,560,822 warrants in total. On 31 December 2021, one program comprising 758,822 warrants expired. The two remaining programs entitle the holder of one warrant to subscribe one new share at SEK 9.87 and 28.73, respectively.

EVENTS AFTER THE END OF THE REPORT PERIOD

No event has happened after the end of the 4th quarter which could significantly change Asarina's financial position.

STATEMENT BY THE BOARD OF DIRECTORS

The Board of Directors and the CEO hereby certify that this report gives a true and fair presentation of the Group's and the parent company's financial position and result of operations and describes material risks and uncertainties facing the Group.

Stockholm, 24 February 2022

Asarina Pharma AB

Board of directors

FINANCIAL CALENDAR FOR 2022

6 April: Annual report 2021

4 May: Annual General Meeting

25 May: Interim report for 1st quarter 2022

25 August: Interim report for 2nd quarter 2022

24 November: Interim report for 3rd quarter 2022

PUBLICATION

The report was submitted for publication by the CEO at 08.00 CET on 24 February 2022.

This report has not been reviewed by the Company's auditors.

CONSOLIDATED INCOME STATEMENT (GROUP)

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC
Net income	0	0	0	0
Other income	0	0	0	0
Total operating income	0	0	0	0
Research and development costs	-7,182	-19,934	-29,922	-63,749
Other external costs	-794	-2,567	-3,802	-7,444
Staff costs	-629	-2,322	-5,441	-10,124
Depreciation	-97	-89	-388	-89
Total operating costs	-8,702	-24,912	-39,553	-81,406
Operating profit/loss	-8,702	-24,912	-39,553	-81,406
Financial income (interest income, currency gains)	8	-254	514	6
Financial cost (interest expenses, currency losses)	-282	-1,219	-527	-1,594
Net financial items	-274	-1,473	-13	-1,588
Profit/loss before tax	-8,976	-26,385	-39,566	-82,994
Tax on profit/loss	6,639	7,738	6,639	7,738
Profit/loss for the period	-2,337	-18,647	-32,927	-75,256

EARNINGS PER SHARE

SEK	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC
Number of shares, average (non-diluted)	18,744,524	18,744,524	18,744,524	18,703,305
Number of shares, average (fully-diluted)	20,320,346	19,620,346	20,038,428	19,572,734
Earnings per share, non-diluted, (SEK)	-0.12	-0.99	-1.76	-4.02
Earnings per share, fully-diluted, (SEK)	-0.12	-0.95	-1.64	-3.84
Number of shares, end of period (non-diluted)	18,744,524	18,744,524	18,744,524	18,744,524
Number of shares, end of period (fully-diluted)	20,320,346	19,620,346	20,320,346	19,620,346

CONSOLIDATED BALANCE SHEET (GROUP)

SEK '000	2021-12-31	2020-12-31
ASSETS		
Non-current assets		
Property, plant and equipment	1,477	1,832
Financial non-current assets	1	1
Total non-current assets	1,478	1,833
Current assets		
<i>Current receivables</i>		
Current tax asset	6,806	7,532
Other receivables	1,401	247
Prepaid expenses and accrued income	47	172
Total current receivables	8,254	7,951
Cash and cash equivalents	21,715	58,501
Total current assets	29,969	66,452
TOTAL ASSETS	31,447	68,285
EQUITY AND LIABILITIES		
Restricted equity		
Share capital	4,686	4,686
Total restricted equity	4,686	4,686
Unrestricted equity		
Share premium reserve	272,813	272,813
Retained earnings	-224,693	-149,731
Profit/loss for the period	-32,927	-75,170
Total unrestricted equity	15,193	47,912
TOTAL EQUITY	19,879	52,598
Non-current liabilities		
Convertible loan	5,300	0
Total non-current liabilities	5,300	0
Current liabilities		
Accounts payable	2,153	11,308
Other current liabilities	462	107
Accrued expenses and prepaid income	3,653	4,272
Total current liabilities	6,268	15,687
Total liabilities	11,568	15,687
TOTAL EQUITY AND LIABILITIES	31,447	68,285

STATEMENT OF CHANGES IN EQUITY (GROUP)

SEK '000	SHARE CAPITAL	SHARE PREMIUM RESERVE	ACCUMULATED LOSSES INCL LOSS FOR THE PERIOD	TOTAL EQUITY
Opening balance 1 January 2020	4,611	264,500	-149,641	119,470
Share issue	75	8,313		8,388
Issue of warrants			504	504
Translation difference			-508	-508
Loss for the period			-75,256	-75,256
Closing balance 31 December 2020	4,686	272,813	-224,901	52,598
Opening balance 1 January 2021	4,686	272,813	-224,901	52,598
Share issue				0
Issue of warrants		371		371
Translation difference			-163	-163
Loss for the period			-32,927	-32,927
Closing balance 31 December 2021	4,686	273,184	-257,991	19,879

CONSOLIDATED STATEMENT OF CASH FLOWS (GROUP)

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC
Operating activities				
Operating profit/loss	-8,702	-24,912	-39,553	-81,406
Adjustment for non-cash flow affecting items				
Depreciation	96	89	387	89
Interest received	15	-1,116	312	6
Interest paid	-289	-344	-528	-1,580
Paid taxes	7,472	7,733	7,503	7,641
Cash flow for operating activities before changes in working capital	-1,408	-18,550	-31,879	-75,250
Cash flow from changes in working capital				
Decrease(+)/Increase(-) in receivables	-1,172	11,293	-1,021	496
Decrease(-)/Increase(+) in liabilities	1,051	466	-9,599	-4,314
Cash flow from operating activities	-1,529	-6,791	-42,499	-79,068
Investment activities				
Acquisition of equipment, tools and installation	0	1	0	-218
Cash flow from investment activities	0	1	0	-218
Financing activities				
Convertible loan received	0	0	5,300	0
Share issue	0	0	0	8,388
Share issue costs	0	0	0	0
Issue of warrants	0	0	371	0
Cash flow from financing activities	0	0	5,671	8,388
Cash flow for the period	-1,529	-6,790	-36,828	-70,898
Cash and cash equivalents at the beginning of the period	23,256	65,111	58,501	129,505
Translation difference	-12	180	42	-106
Cash and cash equivalents at the end of the period	21,715	58,501	21,715	58,501

INCOME STATEMENT - PARENT COMPANY

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC
Net sales	0	0	0	0
Other income	0	181	0	1,454
Total operating income	0	181	0	1,454
Research and development costs	-348	-492	-1,200	-1,822
Other external costs	-390	-873	-2,628	-4,766
Staff costs	683	608	-1,215	-2,712
Total operating costs	-55	-757	-5,043	-9,300
Operating profit/loss	-55	-576	-5,043	-7,846
Financial income (interest income, currency gains)	8	-154	421	338
Financial cost (interest expenses, currency losses)	-266	-701	-351	-821
Net financial items	-258	-855	70	-483
Profit/loss before tax	-313	-1,431	-4,973	-8,329
Tax on profit/loss	0	0	0	0
Profit/loss for the period	-313	-1,431	-4,973	-8,329

BALANCE SHEET - PARENT COMPANY

SEK '000	2021-12-31	2020-12-31
ASSETS		
Non-current assets		
<i>Financial non-current assets</i>		
Shares in subsidiaries	232,405	191,715
Other non-current financial assets	1	1
Financial non-current assets	232,406	191,716
Current assets		
<i>Current receivables</i>		
Receivables from group companies	3,122	13,994
Current tax asset	112	112
Other receivables	1,221	107
Prepaid expenses and accrued income	47	172
Total current receivables	4,502	14,385
Cash and cash equivalents	13,253	42,303
Total current assets	17,755	56,688
TOTAL ASSETS	250,161	248,404
EQUITY AND LIABILITIES		
Restricted equity		
Share capital	4,686	4,686
Total restricted equity	4,686	4,686
Unrestricted equity		
Share premium reserve	272,813	272,813
Retained earnings	-31,972	-24,518
Profit/loss for the period	-4,974	-7,825
Total unrestricted equity	235,867	240,470
TOTAL EQUITY	240,553	245,156
Non-current liabilities		
Convertible loan	5,300	0
Total current liabilities	5,300	0
Current liabilities		
Accounts payable	534	372
Liabilities to group companies	40	0
Other current liabilities	462	107
Accrued expenses and prepaid income	3,272	2,769
Total current liabilities	4,308	3,248
Total liabilities	9,608	3248
TOTAL EQUITY AND LIABILITIES	250,161	248,404

NOTES

1. GENERAL INFORMATION

This interim report covers the parent company Asarina Pharma AB (publ), Corp. Reg. No 556698-0750 and the subsidiaries Asarina Pharma ApS (Denmark) and Asarina Pharma Finans AB.

2. ACCOUNTING PRINCIPLES

This interim report has been prepared in accordance with the Swedish Annual Accounts Act and BFNAR 2012:1 (K3).

The accounting principles adopted in this interim report are consistent with those of the 2020 Annual Report and should be read in conjunction with that annual report.

3. RISKS AND UNCERTAINTIES

RISK MANAGEMENT

The Board of Directors of the company continuously and systematically assess risks in order to identify risks and to take action on them. The internal control environment is primarily comprised of the following five components: control environment, risk assessment, control activities, information and communication and review. Mitigating actions are developed for each identified material risk.

OPERATIONAL RISKS

At the current stage, Asarina's operations mainly consist of pre-clinical and clinical studies in order to demonstrate safety and clinical efficacy of its drug candidates. There is no guarantee that a certain (pre-) clinical trial will generate the required data to enable Asarina to progress to the subsequent development phase of the product candidate. Asarina's goal is to gradually build a portfolio of different pharmaceutical candidates for other indications, thereby reducing risk.

Clinical trials may be delayed and costs for the trial may exceed budget. Prior to initiating a clinical trial, Asarina conducts a thorough assessment of the duration and the costs of the trial to ensure that it has sufficient funding to complete the trial taking into account possible delays and cost increases.

Asarina develops medical products and is dependent on assessments and decisions by relevant authorities such as the EMA in Europe and the FDA in the USA. Asarina cannot guarantee that it will obtain the regulatory approvals required to continue clinical studies and to obtain market approval. In order to mitigate the regulatory risks, the Company retains regulatory consultants as part of the preparation of new clinical studies.

Asarina focuses on therapeutic areas in which few other companies are active. The company conducts extensive monitoring of potential competitive activity within its IP area, in relevant publications and through participation in biotech conferences.

FINANCIAL RISKS

At present, Asarina does not generate any income from product sales or licensing of the Company's IP assets and is therefore dependent upon raising new capital from investors. Asarina aims to have sufficient liquidity for its planned activities for the next 1-2 years. Therefore, Asarina may at any point have discussions with current or potential new investors, which may be interested in injecting new finance into the Company.

Asarina incurs costs mainly in Swedish kronor and Euro. The Company mitigates its exchange rate risk by allocating its financial reserves according to the expected break-down of expenses between the two currencies.

DEFINITION ALTERNATIVE KPIs

KPI	DEFINITION	OBJECTIVE
Equity ratio	Calculated on adjusted equity divided by total assets. Adjusted equity comprises of equity including untaxed reserves deducted with deferred tax liabilities.	The company believes the KPI gives investors information regarding the relation between equity and external financing of the company. The company also believes that the KPS gives investors information about the financial stability and long-term ability.
Return on equity	Result for the period divided by average adjusted equity.	The KPI is included to show the return on the owners invested capital.
Return on total assets	Result before tax with reversal of interest cost in relation to average total assets.	The KPI is included to show the return on the total assets in the company.

RECONCILIATION ALTERNATIVE KPIs

EQUITY RATIO

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC	2020 FULL YEAR
Equity	19,879	52,598	19,879	52,598	52,598
+ Untaxed reserves	0	0	0	0	0
- Deferred tax liability	0	0	0	0	0
Adjusted equity	19,879	52,598	19,879	52,598	52,598
Adjusted equity	19,879	52,598	19,879	52,598	52,598
Total assets	31,447	68,285	31,447	68,285	68,285
Equity ratio, %	63.2	77.0	63.2	77.0	77.0

RETURN ON EQUITY

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC	2020 FULL YEAR
Result for the period	-2,337	-18,647	-32,927	-75,256	-75,256
Average adjusted equity ¹	21,046	61,981	36,239	86,034	86,034
Return on equity, %	-11.1	-30.1	-90.9	-87.5	-87.5

RETURN ON TOTAL ASSETS, %

SEK '000	2021 OCT - DEC	2020 OCT - DEC	2021 JAN - DEC	2020 JAN - DEC	2020 FULL YEAR
Result before tax	-8,976	-26,385	-39,566	-82,994	-82,994
+ Interest costs	282	1,219	527	1,594	1,594
Average total assets ¹	32,087	72,685	49,866	104,090	104,090
Return on total assets, %	-27.1	-34.6	-78.3	-78.2	-78.2

CERTIFIED ADVISER

The company's certified adviser is Erik Penser Bank,
Telephone: +46 (08) 463 80 00
E-mail: certifiedadviser@penser.se

CONTACT PERSONS

Peter Nordkild, CEO
Telephone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO
Telephone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

CONTACT INFORMATION

Asarina Pharma AB (Reg.no 556698-0750)
Fogdevreten 2
S-171 65 Solna

Telephone: +46 8 52 48 44 82
www.asarinapharma.com



ASARINA
P H A R M A

www.asarinapharma.com

ASARINA PHARMA AB | Karolinska Institutet Science Park | Fogdevreten 2, SE 171 65 Solna, Sweden
ASARINA PHARMA ApS | Copenhagen Bio Science Park | Ole Maaløes Vej 3, 2200, København N, Denmark